Charles Schmidt. Show Affiliations »
Abstract
Mesh： See more » AgedAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, Humanized/administration & dosageAntibodies, Monoclonal, Humanized/adverse effectsAntibodies, Monoclonal, Humanized/pharmacologyAntibodies, Monoclonal, Humanized/therapeutic useAntigens, CD19/immunologyChildClinical Trials as TopicDrug-Related Side Effects and Adverse Reactions/diagnosisDrug-Related Side Effects and Adverse Reactions/immunologyDrug-Related Side Effects and Adverse Reactions/pathologyDrug-Related Side Effects and Adverse Reactions/prevention & controlHumansImmunotherapy/adverse effectsInflammation/chemically inducedInflammation/drug therapyInflammation/immunologyInflammation/prevention & controlLenalidomideMaleNeoplasms/immunologyNeoplasms/mortalityNeoplasms/pathologyNeoplasms/therapyNivolumabPrognosisProgrammed Cell Death 1 Receptor/antagonists & inhibitorsRisk ManagementT-Lymphocytes/drug effectsT-Lymphocytes/immunologyT-Lymphocytes/pathologyT-Lymphocytes/transplantationThalidomide/administration & dosageThalidomide/adverse effectsThalidomide/analogs & derivativesThalidomide/therapeutic useTreatment OutcomeVidarabine/analogs & derivativesVidarabine/pharmacology
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigens, CD19PDCD1 protein, humanProgrammed Cell Death 1 ReceptordurvalumabNivolumabThalidomidepomalidomidepembrolizumabLenalidomideVidarabinetocilizumabfludarabine
Year: 2017 PMID： 29293235 DOI： 10.1038/d41586-017-08705-4
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962